A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 968-973

  Tolcher, A W ^a   Quinn, D I ^b   Ferrari, A ^c   Ahmann, F ^d   Giaccone, G ^e   Drake, T ^f   Keating, A ^f   De Bono, J S ^g  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Astellas Pharma Global Development   (United States)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Prostate cancer; Survivin; YM155

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEPANTRONIUM BROMIDE; SURVIVIN; TAXANE DERIVATIVE;

ACIDOSIS; ADULT; AGED; AGITATION; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD CLOTTING DISORDER; BONE PAIN; BRAIN HEMORRHAGE; CACHEXIA; CANCER SURVIVAL; CANDIDURIA; CARDIOPULMONARY INSUFFICIENCY; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DISEASE DURATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEVER; HEMATEMESIS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOXIA; INFECTION; KIDNEY FAILURE; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SPINAL CORD COMPRESSION; STAPHYLOCOCCAL BACTEREMIA; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; WEIGHT REDUCTION; WOUND INFECTION;

EID: 84859422180     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr353     Document Type: Article

References (11)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
2. Zhang M, Latham DE, Delaney MA et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005; 24: 2474-2482.
3. Shariat SF, Lotan Y, Saboorian H et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-757.
4. Tirro E, Consoli ML, Massimino M et al. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66: 4263-4272.
5. Loberg RD, St John LN, Day LL et al. Development of the VCaP androgen-independent model of prostate cancer. Urologic Oncol 2006; 24: 161-168.
6. Nakahara T, Takeuchi M, Kinoyama I et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
7. Minematsu T, Felder L, Oppeneer T et al. Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma. Biomed Chromatogr 2008; 22: 763-769.
8. Simon R. Optimal two-stage designs for phase II clinical trials. Cont Clinical Trials 1989; 10: 1-10.
9. De Bono JS, Oudard S, Ozguroglu M et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010; 28 (Suppl): 15s (Abstr 4508).
10. Tracey L, Perez-Rosado A, Artiga MJ et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005; 206: 123-134.
11. Kaur P, Kallakury BSV, Sheehan CE et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004; 128: 39-43.